Late-breaking oral presentation to feature primary analysis from KYSA-8 registrational trial in stiff person syndrome (SPS)Oral presentation on ...
Positive results from Phase 3 ADAPT OCULUS study show VYVGART’s potential as the first targeted treatment for patients living with ocular MG Additional data from ADAPT SERON – the largest study of ...
Monica Seles first noticed the symptoms of myasthenia gravis — a neuromuscular autoimmune disease she discussed during a recent interview with The Associated Press — while she was swinging a racket ...
NEW HAVEN, Conn. (WTNH) — In today’s Health Headlines, June is Myasthenia Gravis Awareness Month. What is myasthenia gravis, how is it diagnosed, and what treatments are available? Dr. Kunal Desai, ...
Efgartigimod led to statistically significant improvement in key symptoms of ocular myasthenia gravis compared with placebo in a phase 3 trial.
Efgartigimod alfa–hyaluronidase significantly improves ocular symptoms in adults with ocular myasthenia gravis, according to phase 3 trial data.
A 68-year-old man was diagnosed with ocular myasthenia gravis after presenting with double-vision and photophobia. Myasthenia gravis (MG) often begins with ocular symptoms, and sometimes those ...
Data from the randomized MINT trial, presented at the American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) annual meeting, showed that the anti-CD19 monoclonal antibody ...
SAN DIEGO -- Inebilizumab (Uplizna) improved function and reduced disease severity for up to 52 weeks in generalized myasthenia gravis (gMG) patients who were acetylcholine receptor (AChR) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results